Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Make money? Yes, Icahn

This article was originally published in Scrip

Executive Summary

So we know that activist shareholder Carl Icahn, after waging two proxy battles and threatening another to change the leadership and strategy at Forest Laboratories, will trouser a cool $600 million plus profit if Actavis succeeds in its $25bn bid for the US specialty pharma company (scripintelligence.com 19 February 2014 & 18 February 2014). And he is not the only winner as any other shareholders who bought Forest stock mid November 2009, at the same time as Icahn Associates, will have realized a 209% return.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC024481

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel